For the year ending 2025-12-31, SYRE had -$3,702K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -155,203 |
| Depreciation and amortization | 0 |
| Stock-based compensation | 37,614 |
| Acquired in-process research and development | 0 |
| Change in fair value of derivative liability-Contingent Value Right Liability | 29,769 |
| Change in fair value of derivative liability-Forward Contracts | 0 |
| Gain on sale of in-process research and development asset | 10,000 |
| Lease rou asset and leasehold improvement impairment loss | 0 |
| Loss on disposal of long-lived assets | 0 |
| Net (accretion of discount) amortization of premium on marketable securities | 8,090 |
| Interest proceeds from maturities of zero coupon debt securities | 2,130 |
| Amortization of operating lease assets | 0 |
| Other | 0 |
| Prepaid expenses and other assets | 12,819 |
| Accounts payable | 8,238 |
| Deferred revenue | 0 |
| Development receivables | 0 |
| Operating lease liabilities | 0 |
| Accrued and other liabilities | -764 |
| Related party accounts payable | -589 |
| Net cash used in operating activities | -169,252 |
| Cash assumed from asset acquisition of spyre | 0 |
| Proceeds from sale of in-process research & development asset | 7,000 |
| Proceeds from the sale of property plant and equipment | 0 |
| Purchases of marketable securities | 522,214 |
| Proceeds from maturities and sales of marketable securities | 371,739 |
| Net cash (used in) provided by investing activities | -143,475 |
| Proceeds from issuance of private placement, net-Series BNon Voting Convertible Preferred Stock | 0 |
| Proceeds from issuance of common stock in connection with at-the-market offering program, net of issuance costs | 14,750 |
| Proceeds from issuance of common stock in connection with follow-on offering, net of issuance costs | 296,382 |
| Payment of deferred offering costs in connection with shelf registration | 162 |
| Proceeds from issuance of private placement, net-Series ANon Voting Convertible Preferred Stock | 0 |
| Proceeds from issuance of private placement, net-Common Stock | 0 |
| Payment of contingent value rights liability | 5,251 |
| Proceeds from employee stock option exercises and employee stock plan purchases | 3,306 |
| Other financing cash flows | 0 |
| Net cash provided by financing activities | 309,025 |
| Effect of exchange rate on cash, cash equivalents, and restricted cash | 0 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | -3,702 |
Spyre Therapeutics, Inc. (SYRE)
Spyre Therapeutics, Inc. (SYRE)